NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:PATH
- CUSIP: N/A
- Web: N/A
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.14
- P/E Growth: N/A
Dividend:
Frequently Asked Questions for NuPathe (NASDAQ:PATH)
What is NuPathe's stock symbol?
NuPathe trades on the NASDAQ under the ticker symbol "PATH."
Who are some of NuPathe's key competitors?
Some companies that are related to NuPathe include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Veeva Systems (VEEV), West Pharmaceutical Services (WST), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV) and Puma Biotechnology (PBYI).
How do I buy NuPathe stock?
Shares of NuPathe can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuPathe's stock price today?
One share of NuPathe stock can currently be purchased for approximately $4.25.
MarketBeat Community Rating for NuPathe (NASDAQ PATH)MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for NuPathe (NASDAQ:PATH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for NuPathe (NASDAQ:PATH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/28/2016 | Wedbush | Downgrade | Outperform -> Neutral | $8.00 -> $5.00 | N/A |  |
(Data available from 7/23/2015 forward)
Earnings History for NuPathe (NASDAQ:PATH)Earnings History by Quarter for NuPathe (NASDAQ PATH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2013 | Q3 | ($0.20) | ($0.25) | | | View | Listen | |
| 8/8/2013 | Q2 2013 | ($0.20) | ($0.16) | | | View | N/A | |
| 5/14/2013 | Q1 2013 | ($0.17) | ($0.68) | | | View | N/A | |
| 3/26/2013 | Q4 2012 | ($0.33) | ($1.16) | | | View | N/A | |
| 11/12/2012 | Q312 | ($0.38) | ($0.42) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for NuPathe (NASDAQ:PATH)Current Year EPS Consensus Estimate: $-1.26 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS
Dividend History for NuPathe (NASDAQ:PATH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for NuPathe (NASDAQ:PATH)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for NuPathe (NASDAQ:PATH)
Latest Headlines for NuPathe (NASDAQ:PATH)
| Source: |
|
NuPathe (PATH) Chart for Sunday, July, 23, 2017
